These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 18804131)

  • 41. Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice.
    Dong L; Liu F; Fairman J; Hong DK; Lewis DB; Monath T; Warner JF; Belser JA; Patel J; Hancock K; Katz JM; Lu X
    Vaccine; 2012 Jan; 30(2):254-64. PubMed ID: 22085545
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intranasal administration of a live non-pathogenic avian H5N1 influenza virus from a virus library confers protective immunity against H5N1 highly pathogenic avian influenza virus infection in mice: comparison of formulations and administration routes of vaccines.
    Kashima Y; Ikeda M; Itoh Y; Sakoda Y; Nagata T; Miyake T; Soda K; Ozaki H; Nakayama M; Shibuya H; Okamatsu M; Ishigaki H; Ishida H; Sawai T; Kawaoka Y; Kida H; Ogasawara K
    Vaccine; 2009 Dec; 27(52):7402-8. PubMed ID: 19747993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.
    Tompkins SM; Zhao ZS; Lo CY; Misplon JA; Liu T; Ye Z; Hogan RJ; Wu Z; Benton KA; Tumpey TM; Epstein SL
    Emerg Infect Dis; 2007 Mar; 13(3):426-35. PubMed ID: 17552096
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
    Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.
    Govorkova EA; Webby RJ; Humberd J; Seiler JP; Webster RG
    J Infect Dis; 2006 Jul; 194(2):159-67. PubMed ID: 16779721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.
    Höschler K; Gopal R; Andrews N; Saville M; Pepin S; Wood J; Zambon MC
    Influenza Other Respir Viruses; 2007; 1(5-6):199-206. PubMed ID: 19453427
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of protection against H5N1 influenza virus in mouse offspring provided by maternal vaccination with HA DNA and inactivated vaccine.
    Zhang F; Fang F; Chang H; Peng B; Wu J; Chen J; Wang H; Chen Z
    Arch Virol; 2013 Jun; 158(6):1253-65. PubMed ID: 23385327
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains.
    Fazekas G; Martosne-Mendi R; Jankovics I; Szilvasy I; Vajo Z
    Clin Vaccine Immunol; 2009 Apr; 16(4):437-43. PubMed ID: 19020111
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protection of pregnant mice, fetuses and neonates from lethality of H5N1 influenza viruses by maternal vaccination.
    Hwang SD; Shin JS; Ku KB; Kim HS; Cho SW; Seo SH
    Vaccine; 2010 Apr; 28(17):2957-64. PubMed ID: 20188684
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
    Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
    Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
    Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
    PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
    Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
    Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab')2 against highly pathogenic avian influenza H5N1 in mice.
    Zhao Z; Yan F; Chen Z; Luo D; Duan Y; Yang P; Li Z; Peng D; Liu X; Wang X
    Int Immunopharmacol; 2011 Dec; 11(12):2000-6. PubMed ID: 21906698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone.
    Pushko P; Tretyakova I; Hidajat R; Sun X; Belser JA; Tumpey TM
    Vaccine; 2018 Jul; 36(29):4346-4353. PubMed ID: 29885769
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus.
    Lu X; Liu F; Zeng H; Sheu T; Achenbach JE; Veguilla V; Gubareva LV; Garten R; Smith C; Yang H; Stevens J; Xu X; Katz JM; Tumpey TM
    Virology; 2014 Apr; 454-455():169-75. PubMed ID: 24725943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine.
    Leroux-Roels I; Bernhard R; Gérard P; Dramé M; Hanon E; Leroux-Roels G
    PLoS One; 2008 Feb; 3(2):e1665. PubMed ID: 18301743
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.
    Hoelscher MA; Singh N; Garg S; Jayashankar L; Veguilla V; Pandey A; Matsuoka Y; Katz JM; Donis R; Mittal SK; Sambhara S
    J Infect Dis; 2008 Apr; 197(8):1185-8. PubMed ID: 18462165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential risk of repeated nasal vaccination that induces allergic reaction with mucosal IgE and airway eosinophilic infiltration in cynomolgus macaques infected with H5N1 highly pathogenic avian influenza virus.
    Nakayama M; Itoh Y; Shichinohe S; Nakabayashi R; Ishigaki H; Sakoda Y; Le QM; Kawaoka Y; Kida H; Ogasawara K
    Vaccine; 2017 Feb; 35(7):1008-1017. PubMed ID: 28109707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.